There are two ongoing Phase III studies with the Diamyd
® vaccine, one in the US and one in Europe. In the US there is also an ongoing Phase I trial with the NTDDS product; NP2. Furthermore there are initiated and ongoing independent trials with the Diamyd
® vaccine, please see links in the right column for more information.
PIPELINE
Diamyd Medical's pipeline is based on two patent-protected technology platforms, GAD for treatment of autoimmune diabetes and NTDDS for treatment of chronic pain and other neurological complications of diabetes. The company's most advanced project, the GAD-based diabetes vaccine Diamyd
®, has proven to slow or arrest the destruction of beta cells characteristic of autoimmune diabetes. Thereby the patient's endogenous insulin production is preserved.
